Table 2.

Response to gefitinib or erlotinib in NSCLC patients with exon 19 deletions or L858R point mutations

ResponseExon 19 deletion (N = 22)L858R mutation (N = 10)P
Best response
    CR20
    PR145
    SD65
    PD00
Response rate73%50%0.25
Disease control rate100%100%1.00
Median duration of treatment (mo)
    CR/PR16130.46
    SD26100.01
  • Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.